246 related articles for article (PubMed ID: 32238005)
1. Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis.
Fujii M; Karumai T; Yamamoto R; Kobayashi E; Ogawa K; Tounai M; Lipman J; Hayashi Y
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):415-430. PubMed ID: 32238005
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.
Roberts JK; Stockmann C; Constance JE; Stiers J; Spigarelli MG; Ward RM; Sherwin CM
Clin Pharmacokinet; 2014 Jul; 53(7):581-610. PubMed ID: 24871768
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
Roberts JA; Lipman J
Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
[TBL] [Abstract][Full Text] [Related]
5. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis.
Lutsar I; Metsvaht T
Curr Opin Infect Dis; 2010 Jun; 23(3):201-7. PubMed ID: 20179595
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic therapy in sepsis: No next time for a second chance!
Shahrami B; Sharif M; Sefidani Forough A; Najmeddin F; Arabzadeh AA; Mojtahedzadeh M
J Clin Pharm Ther; 2021 Aug; 46(4):872-876. PubMed ID: 33710622
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].
Bellmann R
Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):162-6. PubMed ID: 24643839
[TBL] [Abstract][Full Text] [Related]
9. [Adequate anti-infective treatment : Importance of individual dosing and application].
Brinkmann A; Röhr AC; Köberer A; Fuchs T; Krüger WA; König C; Richter D; Weigand MA; Frey OR
Anaesthesist; 2018 Jun; 67(6):461-476. PubMed ID: 29766208
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic monitoring of antimicrobial agents in pediatrics. Review based on Latin American experiences].
Zylbersztajn B; Barraza M; Torres JP; Morales J
Rev Chilena Infectol; 2018; 35(1):22-28. PubMed ID: 29652968
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.
Phe K; Heil EL; Tam VH
J Infect Dis; 2020 Jul; 222(Suppl 2):S132-S141. PubMed ID: 32691832
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
Tsai D; Lipman J; Roberts JA
Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
[TBL] [Abstract][Full Text] [Related]
13. The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis.
Bartoletti M; Lewis RE; Giannella M; Tedeschi S; Viale P
Expert Rev Anti Infect Ther; 2018 Oct; 16(10):771-779. PubMed ID: 30221562
[TBL] [Abstract][Full Text] [Related]
14. Updated antimicrobial dosing recommendations for obese patients.
Castro-Balado A; Varela-Rey I; Mejuto B; Mondelo-García C; Zarra-Ferro I; Rodríguez-Jato T; Fernández-Ferreiro A
Antimicrob Agents Chemother; 2024 May; 68(5):e0171923. PubMed ID: 38526051
[TBL] [Abstract][Full Text] [Related]
15. Benefits of prolonged infusion of beta-lactam antibiotics in patients with sepsis: personal perspectives.
Rafailidis PI; Falagas ME
Expert Rev Anti Infect Ther; 2020 Oct; 18(10):957-966. PubMed ID: 32564641
[TBL] [Abstract][Full Text] [Related]
16. Optimization of dosing regimens and dosing in special populations.
Sime FB; Roberts MS; Roberts JA
Clin Microbiol Infect; 2015 Oct; 21(10):886-93. PubMed ID: 25980350
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
Varghese JM; Roberts JA; Lipman J
Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Guidance for Antibiotic Dosing in Obese Adults.
Meng L; Mui E; Holubar MK; Deresinski SC
Pharmacotherapy; 2017 Nov; 37(11):1415-1431. PubMed ID: 28869666
[TBL] [Abstract][Full Text] [Related]
19. Can we transfer pharmacokinetics/pharmacodynamics of antimicrobials into clinical practice?
Scaglione F
Int J Antimicrob Agents; 2015 Dec; 46 Suppl 1():S40-2. PubMed ID: 26607342
[TBL] [Abstract][Full Text] [Related]
20. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
